COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Does Deficiency in Vitamin D Induced Hypercoagulation or Thrombin Generation

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01761669
Recruitment Status : Completed
First Posted : January 7, 2013
Last Update Posted : November 3, 2016
Information provided by (Responsible Party):
Elias mazen, HaEmek Medical Center, Israel

Brief Summary:

Working hypothesis and aims: The aim of our study is to investigate whether vitamin D deficiency could cause increased thrombin generation and a hypercoagulable state healthy volunteers.


In total 400 healthy volunteers are planned for inclusion in this trial. After signing an informed consent two blood samples will be obtained from each participant.

Expected results: invastigator expect to find that volunteers with vitamin D deficiency will have thrombin generation curve compatible with hypercoagulable state and returning to normal after treatment with vitamin D

Condition or disease Intervention/treatment
Cardiovascular Disease Drug: Vitamin D

Layout table for study information
Study Type : Observational [Patient Registry]
Actual Enrollment : 400 participants
Time Perspective: Prospective
Target Follow-Up Duration: 3 Months
Study Start Date : April 2013
Actual Primary Completion Date : June 2013
Actual Study Completion Date : July 2013

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Vitamin D
Drug Information available for: Vitamin D

Group/Cohort Intervention/treatment
healthy voulnters Drug: Vitamin D

Primary Outcome Measures :
  1. the correlation between vitamin D levels and endogenous thrombin potential [ Time Frame: 3 month ]
    one blood test

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
400 healthy volunteers

Inclusion Criteria: age >18 healthy naive to drug treatment -

Exclusion Criteria:

no exc criteria


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01761669

Layout table for location information
Afula, Israel, 19101
Sponsors and Collaborators
HaEmek Medical Center, Israel
Layout table for investigator information
Principal Investigator: mazen elias, MD Emek Medical Center
Additional Information:

Layout table for additonal information
Responsible Party: Elias mazen, Director of Internal Medicine C, HaEmek Medical Center, Israel Identifier: NCT01761669    
Other Study ID Numbers: vitamin D
First Posted: January 7, 2013    Key Record Dates
Last Update Posted: November 3, 2016
Last Verified: December 2014
Additional relevant MeSH terms:
Layout table for MeSH terms
Cardiovascular Diseases
Vitamin D
Growth Substances
Physiological Effects of Drugs
Bone Density Conservation Agents